top of page


European Commission expands Oncopeptides' Pepaxti authorisation to third-line multiple myeloma
The European Commission has approved an expansion of Oncopeptides' Pepaxti label into third-line multiple myeloma treatment, broadening eligibility after two prior lines of therapy and removing the previous triple-class refractory requirement.

nuaxia
4 days ago2 min read


Karyopharm plans Ayrmid merger through Chapter 11 restructuring with $55 million financing commitment
Karyopharm Therapeutics has announced a proposed merger with Ayrmid through a court-supervised Chapter 11 restructuring process, supported by a $55 million additional financing commitment.

nuaxia
Nov 52 min read


European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma
The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting.

nuaxia
Oct 272 min read


GSK acquires Chimagen trispecific T-cell engager programme in deal worth up to $750m
GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.

nuaxia
Sep 162 min read


FDA clears Wandercraft’s Eve self-balancing exoskeleton for personal use in adults with spinal cord injury
The clearance extends Wandercraft’s self-balancing exoskeleton technology beyond supervised rehabilitation, allowing eligible adults with spinal cord injuries to use Eve for hands-free upright mobility and daily activities with a trained companion.

nuaxia
Aug 142 min read


FDA grants accelerated approval to Zenbexus combination for previously treated multiple myeloma
The approval provides adults who have received at least one prior line of therapy with a new iberdomide-based combination, supported by higher minimal residual disease-negative complete response rates than the comparator regimen in EXCALIBER-RRMM.

nuaxia
Aug 142 min read


FDA Approves Subcutaneous Sarclisa (Isatuximab-Irfc) for Multiple Myeloma Treatment
New formulation expands Sanofi’s Sarclisa portfolio by offering a subcutaneous delivery option across multiple myeloma treatment settings, including newly diagnosed, relapsed and refractory disease.

nuaxia
Jul 103 min read


FDA Approves Tecvayli Plus Darzalex Faspro for Relapsed or Refractory Multiple Myeloma
Combination therapy demonstrates significant improvements in progression-free and overall survival in adults after at least one prior treatment, offering a new standard-of-care option.

nuaxia
Mar 92 min read
bottom of page